NeuBase Therapeutics, Inc.: Nasdaq/NYSE listing notice — NeuBase receives Nasdaq non-compliance notice for late 10-K filing; has until June 3 to submit plan

NeuBase Therapeutics, Inc.

Failed to file Annual Report on Form 10-K for FY2023 ended Dec 31, 2023.
Received notice from Nasdaq on April 4, 2024; listing not immediately affected.
Must submit compliance plan by June 3, 2024; if accepted, exception may extend to Sept 30, 2024.
Failure to regain compliance could result in delisting of NBSE common stock.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NeuBase Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 4, 2024, NeuBase Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of the Company’s failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commiss

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-044287

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.